The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid Tumors
Abstract
PURPOSE: This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract (GTE) once daily or three times daily. PATIENTS AND METHODS: Cohorts of three or more adult cancer patients were administered oral GTE with water after meals one or three times daily for 4 weeks, to a maximum of 6 months, depending on disease response and patient tolerance. Pharmacokinetic analyses were encouraged but optional. RESULTS: Dose levels of 0.5 to 5.05 g/m 2 qd and 1.0 to 2.2 g/m 2 tid were explored. A total of 49 patients were studied. Patient characteristics: median age, 57 years (range, 27 to 77 years); 23 patients were women (47%); 98% had a Zubrod PS of 1%; 98% had PS of 1; and 21 had non–small-cell lung, 19 had head & neck cancer, three had mesothelioma, and six had other. Mild to moderate toxicities were seen at most dose levels and promptly reversed on discontinuation of GTE. Dose-limiting toxicities were caffeine related and included neurologic and gastrointestinal effects. The maximum-tolerated dose was 4.2 g/m 2 once daily or 1.0 g/m 2 three times daily. No major responses occurred; 10 patients with stable disease completed 6 months of GTE. Pharmacokinetic analyses found accumulation of caffeine levels that were dose dependent, whereas epigallocatechin gallate levels did not accumulate nor appear dose related. CONCLUSION: A dose of 1.0 g/m 2 tid (equivalent to 7 to 8 Japanese cups [120 mL] of green tea three times daily) is recommended for future studies. The side effects of this preparation of GTE were caffeine related. Oral GTE at the doses studied can be taken safely for at least 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lou, Y.-R., Lu, Y.-P., Xie, J.-G., Huang, M.-T., & Conney, A. H. (1999) · Nutrition and Cancer · doi:10.1207/s15327914nc330205 · Cited by 105
Cited by
Phase I Clinical Trial of Oral Curcumin
Sharma, R. A., Euden, S. A., Platton, S. L., Cooke, D. N., Shafayat, A., Hewitt, H. R., Marczylo, T. H., Morgan, B., Hemingway, D., Plummer, S. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0744 · Cited by 1,257
Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications
Zaveri, N. T. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.006 · Cited by 810
Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways
Ramos, S. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700326 · Cited by 696
Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives
Nagle, D. G., Ferreira, D., & Zhou, Y.-D. (2006) · Phytochemistry · doi:10.1016/j.phytochem.2006.06.020 · Cited by 626
Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention
Ramos, S. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.11.004 · Cited by 617
Perspectives for Cancer Prevention With Natural Compounds
Amin, A. R. M. R., Kucuk, O., Khuri, F. R., & Shin, D. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6235 · Cited by 572
Self-citationCancer Prevention With Natural Compounds
Gullett, N. P., Ruhul Amin, A. R. M., Bayraktar, S., Pezzuto, J. M., Shin, D. M., Khuri, F. R., Aggarwal, B. B., Surh, Y.-J., & Kucuk, O. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.06.014 · Cited by 485
Self-citationThomasset, S. C., Berry, D. P., Garcea, G., Marczylo, T., Steward, W. P., & Gescher, A. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22419 · Cited by 406
Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review
AL Zahrani, N. A., El-Shishtawy, R. M., & Asiri, A. M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112609 · Cited by 346
Green tea (Camellia sinensis) for the prevention of cancer
Filippini, T., Malavolti, M., Borrelli, F., Izzo, A. A., Fairweather-Tait, S. J., Horneber, M., & Vinceti, M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005004.pub3 · Cited by 327
Aktas, O., Prozorovski, T., Smorodchenko, A., Savaskan, N. E., Lauster, R., Kloetzel, P.-M., Infante-Duarte, C., Brocke, S., & Zipp, F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5794 · Cited by 316
Safety of Green Tea Extracts: A Systematic Review by the US Pharmacopeia
Sarma, D. N., Barrett, M. L., Chavez, M. L., Gardiner, P., Ko, R., Mahady, G. B., Marles, R. J., Pellicore, L. S., Giancaspro, G. I., & Low Dog, T. (2008) · Drug Safety · doi:10.2165/00002018-200831060-00003 · Cited by 308
Role of Phytochemicals in Cancer Chemoprevention: Insights
George, B. P., Chandran, R., & Abrahamse, H. (2021) · Antioxidants · doi:10.3390/antiox10091455 · Cited by 295
Jatoi, A., Ellison, N., Burch, P. A., Sloan, J. A., Dakhil, S. R., Novotny, P., Tan, W., Fitch, T. R., Rowland, K. M., Young, C. Y. F., et al. (2003) · Cancer · doi:10.1002/cncr.11200 · Cited by 284
Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols
Garg, A. K., Buchholz, T. A., & Aggarwal, B. B. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1630 · Cited by 278
Na, H.-K., Kim, E.-H., Jung, J.-H., Lee, H.-H., Hyun, J.-W., & Surh, Y.-J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.003 · Cited by 268
Tsao, A. S., Liu, D., Martin, J., Tang, X.-M., Lee, J. J., El-Naggar, A. K., Wistuba, I., Culotta, K. S., Mao, L., Gillenwater, A., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0121 · Cited by 253
Self-citation
Metadata
- Authors
- Pisters, K. M. W., Newman, R. A., Coldman, B., Shin, D. M., Khuri, F. R., Hong, W. K., Glisson, B. S., & Lee, J. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-15
- Volume
- 19
- Issue
- 6
- Pages
- 1830-1838
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1896985636
- Cited by
- 243
- References
- 1
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.